Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageWe are a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. We offer Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis ("PPP"). We are advancing our Phase 3-ready pipeline product, XP-8121, once-weekly subcutaneous ("SC") levothyroxine, which leverages our proprietary technology XeriSol.
In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR
Business segments
Jun 2026 · $92.1MThe company’s own SEC segment disclosure.
- Recorlev$56.8M62%
- Gvoke$22.5M24%
- Keveyis$11.7M13%
- Royalty Contract And Other$1.1M1%
Xeris Biopharma Holdings, Inc. (XERS) reported revenue of $83M in Q1 2026 (quarter ended Mar 31, 2026), up 38% from the same quarter a year earlier. That came with a gross margin of 87% and net income of $2.2M (2.7% of revenue). For the full year FY2025, revenue was $292M (+44% year on year) and net income $554K. Its largest product in Jun 2026 was Recorlev at $57M, 62% of the disclosed total, well ahead of Gvoke at 24%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #14 of 29 by Smart Score